InnoCan Pharma (HAM:IP40) ROC (Joel Greenblatt) %: -222.22% (As of Mar. 2026)


HAM:IP40 InnoCan Pharma Corp HAM:IP40
63 GF Score
Price €1.80
GF Value €7.83
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma ROC (Joel Greenblatt) %?

InnoCan Pharma HAM:IP40 +22.87% 63 ROC (Joel Greenblatt) % is -222.22% as of Mar. 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 63/100 and a GF Value™ of €7.83 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,970 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 94.82% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. InnoCan Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -222.22%.

The historical rank and industry rank for InnoCan Pharma's ROC (Joel Greenblatt) % or its related term are showing as below:

HAM:IP40' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -39175   Med: -3405.92   Max: 114.6
Current: -68.83

During the past 8 years, InnoCan Pharma's highest ROC (Joel Greenblatt) % was 114.60%. The lowest was -39175.00%. And the median was -3405.92%.

HAM:IP40's ROC (Joel Greenblatt) % is ranked worse than
94.82% of 1970 companies
in the Consumer Packaged Goods industry
Industry Median: 11.985 vs HAM:IP40: -68.83

InnoCan Pharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


InnoCan Pharma  (HAM:IP40) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


InnoCan Pharma ROC (Joel Greenblatt) % Related Terms


InnoCan Pharma ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma ROC (Joel Greenblatt) % Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -18,976.60 -684.33 -643.86 114.36 5.49

InnoCan Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.50 -93.45 -4,884.71 782.77 -222.22

HAM:IP40 vs PG, CL, KVUE: ROC (Joel Greenblatt) % Comparison

For the Household & Personal Products subindustry, InnoCan Pharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCan Pharma ROC (Joel Greenblatt) % vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's ROC (Joel Greenblatt) % falls into.


HAM:IP40
63GF Score
InnoCan Pharma Corp HAM:IP40
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 1.861 + 0.534) - (0.828 + 0 + 0.329)
=1.238

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 1.884 + 0.571) - (0.97 + 0 + 0.327)
=1.158

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of InnoCan Pharma for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.82/( ( (0.073 + max(1.238, 0)) + (0.069 + max(1.158, 0)) )/ 2 )
=-2.82/( ( 1.311 + 1.227 )/ 2 )
=-2.82/1.269
=-222.22 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -222.22% mean?
InnoCan Pharma (HAM:IP40) has a ROC (Joel Greenblatt) % of -222.22% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #1868 out of 1970 companies in the Consumer Packaged Goods industry, placing it in the top 94.8%.
Is InnoCan Pharma's ROC (Joel Greenblatt) % too high?
InnoCan Pharma's current ROC (Joel Greenblatt) % is -222.22%. Based on the distribution chart, InnoCan Pharma ranks #1868 out of 1970 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, InnoCan Pharma has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's ROC (Joel Greenblatt) % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #1868 out of 1970 companies for ROC (Joel Greenblatt) %. This places InnoCan Pharma in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Consumer Packaged Goods company?
The median ROC (Joel Greenblatt) % among Consumer Packaged Goods companies is 11.99, based on 1,970 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median ROC (Joel Greenblatt) % is 11.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current ROC (Joel Greenblatt) % is -222.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €7.83, compared to a current price of €1.80 — trading 77% below its estimated fair value. The current ROC (Joel Greenblatt) % is -222.22%. InnoCan Pharma's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current ROC (Joel Greenblatt) % is -222.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.80 is trading 77% below its estimated GF Value™ of €7.83. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for HAM:IP40:

  • ROC (Joel Greenblatt) %: -222.22%
  • GF Value™: €7.83 vs. price of €1.80 (77% below fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InnoCan Pharma Business Description

Other Exchanges INNPF:USAINNO:Canada
Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
63GF Score

Get the complete analysis for HAM:IP40

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.80
Price
€7.83
GF Value